Feb 27, 2025 · Norlase is reinventing ophthalmic lasers for treatment of retina and glaucoma disorders. Latest in laser technology offering high clinical and practice value.

Norlase is an emerging global ophthalmic medical device company developing next-generation laser solutions for the treatment of retina and glaucoma disease. Norlase is comprised of worldwide industry leaders and experts in ophthalmology, laser technology, medical device development and customer care.

ECHO combines the ultra-compact Norlase laser engine with industry-first MEMS scanning technology. This fully integrated design allows a single device that provides laser, scanner and delivery device in one housing, offering true portability and treatment flexibility.

Mar 3, 2025 · Norlase, a two-time PRISM Award winner and developer of ophthalmic laser technology, has secured funding to expand the commercialization of its portable ophthalmic lasers. Courtesy of Davy Denke. On a technical level, the financing will support the development and market access of Norlase’s innovative portable ophthalmic lasers, designed to ...

May 8, 2023 · Norlase has received 510(k) clearance from the US Food and Drug Administration (FDA) and CE Mark approval for its ultra-portable ECHO Green Pattern Laser photocoagulator. Using MEMS technology, the scanning laser photocoagulator is easily installed on …

Nov 11, 2023 · Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.

Jan 27, 2025 · Norlase, a leading global ophthalmic laser manufacturer, announced the immediate commercial launch and FDA 510(k) clearance and CE Mark for Norlase LYNX. LYNX is the world’s first and only pattern scanning laser indirect ophthalmoscope and is battery-powered to provide surgeons with an untethered laser solution.

ECHO combines the ultra-compact Norlase laser engine with industry-first MEMS scanning technology. This fully integrated design allows a single device that provides laser, scanner and delivery device in one housing, offering true portability and treatment flexibility.

Jan 27, 2025 · Ophthalmic laser manufacturer Norlase has announced the immediate commercial launch and FDA 510(k) clearance and CE Mark for LYNX, the company’s pattern scanning laser indirect ophthalmoscope (LIO).

Mar 6, 2025 · Norlase announced the FDA 510(k) clearance and immediate commercial launch of LEAF, the company’s flagship laser product for the treatment of retina and glaucoma disease. LEAF allows ophthalmologists to perform laser therapy in almost any exam room, with minimal set-up time and physical space required.